Literature DB >> 226028

Membranous nephropathy. Its association with multicentric angiofollicular lymph node hyperplasia.

D D Weisenburger.   

Abstract

Multicentric angiofollicular lymph node hyperplasia of the plasma cell type with systemic manifestations developed in a 51-year-old man. One year later, the nephrotic syndrome due to typical immune complex mediated membranous nephropathy developed. Elevated titers to Epstein-Barr viral antigens suggesting reactivation of a latent infection were present. The patient has required conservative medical management only. The association of membranous nephropathy with angiofollicular lymph node hyperplasia lends further evidence to the postulate that the disorder is a manifestation of chronic immune stimulation by a foreign antigen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226028

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

1.  Giant lymph node hyperplasia (Castleman's disease): a clinical study of eight patients.

Authors:  Y Baruch; Y Ben-Arie; H Kerner; M Lorber; L A Best; R Gershoni-Baruch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

2.  Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.

Authors:  Takeshi Tosaki; Masahiro Okabe; Tomo Suzuki; Akihiro Shimizu; Kentaro Koike; Nobuo Tsuboi; Tetsuya Kawamura; Ryuji Ohashi; Shingo Yano; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2021-01-02

3.  Multicentric angiofollicular lymph node hyperplasia.

Authors:  M Al-Jabi; W T McCaughey
Journal:  Can Med Assoc J       Date:  1981-04-15       Impact factor: 8.262

4.  Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.

Authors:  M C Kinney; D S Hummell; P M Villiger; A Hourigan; L Rollins-Smith; A D Glick; A R Lawton
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

5.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

Review 6.  Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.

Authors:  Ryosuke Saiki; Kan Katayama; Yosuke Hirabayashi; Keiko Oda; Mika Fujimoto; Tomohiro Murata; Ayako Nakajima; Kaoru Dohi
Journal:  BMC Nephrol       Date:  2021-06-09       Impact factor: 2.388

7.  A rare case of renal thrombotic microangiopathy associated with Castleman's disease.

Authors:  Anubha Mutneja; L Nicholas Cossey; Helen Liapis; Ying Maggie Chen
Journal:  BMC Nephrol       Date:  2017-02-10       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.